Skip to main content

$17.88 -0.10 (-0.56%)

High

$18.20

Low

$17.50

Trades

1,245

Turnover

$1,190,837

Volume

66,664
30 June 2023 at 4:10pm
Register to track CUV and receive email alerts.
Subject
CUV Ann: Appendix 4G and Corporate Governance Statement

CUV Ann: Revenue Growth Drives CLINUVEL's Full Year Profit

CUV Ann: Dividend/Distribution - CUV

CUV Ann: Appendix 4E and Annual Report 2022

CUV Ann: CLINUVEL Newsletter IV - August 2022

CUV Ann: Chair's Letter

CUV Ann: PRENUMBRA Instant Formulation for Stroke

CUV Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CUV Ann: Change of Director's Interest Notice

CUV Ann: CLINUVEL Newsletter III - June 2022

CUV Ann: Change of Director's Interest Notice

CUV Ann: Ceasing to be a substantial holder

CUV Ann: H.C. Wainwright Global Investment Conference Presentation

CUV Ann: Change in substantial holding

CUV Ann: Becoming a substantial holder

CUV Ann: CLINUVEL Strategic Update IV - May 2022

CUV Ann: Change of Director's Interest Notice x 2

CUV Ann: CLINUVEL Progresses CUV104 Vitiligo Study

CUV Ann: Notification regarding unquoted securities - CUV

CUV Ann: Positive Final Results in Stroke Study CUV801

CUV Ann: CEO Letter

CUV Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CUV Ann: Notice of ceasing to be a substantial holder

CUV Ann: Initial Director's Interest Notice

CUV Ann: Chair's Letter

CUV Ann: CLINUVEL appoints new Non-Executive Director

CUV Ann: CLINUVEL Extends CEO Employment Agreement

CUV Ann: CLINUVEL Newsletter II - March 2022

CUV Ann: First XP-V Patient Treated in Third CUV DNA Repair Study

CUV Ann: Change of Director's Interest Notice

CUV Ann: ACTH Manufacturing Update

CUV Ann: afamelanotide in Stroke (AIS) - Positive Preliminary Results

CUV Ann: Change of Director's Interest Notice

CUV Ann: CEO Letter

CUV Ann: CLINUVEL Reports December Half Year Operating Results

CUV Ann: Appendix 4D Half Year Report

CUV Ann: Operations Update I Financial Results Webinar

CUV Ann: CLINUVEL Expands DNA Repair Program with 2nd Study

CUV Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CUV Ann: CLINUVEL Newsletter I - January 22

CUV Ann: SCENESSE Continued in Germany

CUV Ann: Change of Director's Interest Notice

CUV Ann: Notification of cessation of securities - CUV

CUV Ann: CLINUVEL completes enrolment in CUV801 Stroke Study

CUV Ann: Presentation - H.C. Wainwright Bioconnect Conference 2022

CUV Ann: Progress update to DNA Repair Program

CUV Ann: Chair Letter

CUV Ann: CLINUVEL Newsletter 6 - December 2021

CUV Ann: CLINUVEL Study to Evaluate SCENESSE as Vitiligo Monotherapy

CUV Ann: CLINUVEL Newsletter 5 - November 2021

Register to track CUV and receive email alerts.

Similar Companies

CSL ...
CSL
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX